Accelerated Pharma (Accelerated Pharma) Accounts Receivable : $0.00 Mil (As of Mar. 2017)

View and export this data going back to 2016. Start your Free Trial

What is Accelerated Pharma Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Accelerated Pharma's accounts receivables for the quarter that ended in Mar. 2017 was $0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Accelerated Pharma's Net-Net Working Capital per share for the quarter that ended in Mar. 2017 was $-1.03.

Accelerated Pharma Accounts Receivable Historical Data

The historical data trend for Accelerated Pharma's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accelerated Pharma Accounts Receivable Chart

Accelerated Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Accounts Receivable

Accelerated Pharma Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17
Accounts Receivable	Get a 7-Day Free Trial			-	-	-	-	-

Accelerated Pharma Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Accelerated Pharma Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Accelerated Pharma's Days Sales Outstanding for the quarter that ended in Mar. 2017 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Accelerated Pharma's accounts receivable are only considered to be worth 75% of book value:

Accelerated Pharma's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2017 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(0.063	+	0.75 * 0	+	0.5 * 0	-	7.189
-	0	-	0)	/	6.89
=	-1.03

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Accelerated Pharma Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Accelerated Pharma's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Accelerated Pharma (Accelerated Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Accelerated Pharma Inc (NAS:ACCP) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Accelerated Pharma Inc, is a Delaware corporation organized on May 12, 2014. It is a biopharmaceutical company focused on utilizing its genomic technology to enhance the development and commercialization of pharmaceutical products. Its lead product candidate is Picoplatin, a new generation platinum-based cancer therapy that has the potential for use in different formulations, as a single agent or in combination with other anti-cancer agents, to treat multiple cancer indications.

Accelerated Pharma (Accelerated Pharma) Headlines

No Headlines